GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nicox SA (XPAR:ALCOX) » Definitions » Net Margin %

Nicox (XPAR:ALCOX) Net Margin % : -70.47% (As of Jun. 2024)


View and export this data going back to 1999. Start your Free Trial

What is Nicox Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. Nicox's Net Income for the six months ended in Jun. 2024 was €-4.28 Mil. Nicox's Revenue for the six months ended in Jun. 2024 was €6.07 Mil. Therefore, Nicox's net margin for the quarter that ended in Jun. 2024 was -70.47%.

The historical rank and industry rank for Nicox's Net Margin % or its related term are showing as below:

XPAR:ALCOX' s Net Margin % Range Over the Past 10 Years
Min: -118968.75   Med: -388.54   Max: -23.99
Current: -126.37


XPAR:ALCOX's Net Margin % is ranked worse than
50.75% of 995 companies
in the Biotechnology industry
Industry Median: -114.45 vs XPAR:ALCOX: -126.37

Nicox Net Margin % Historical Data

The historical data trend for Nicox's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nicox Net Margin % Chart

Nicox Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -229.08 -125.48 -509.86 -596.81 -314.19

Nicox Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -732.39 -489.01 -460.19 -212.85 -70.47

Competitive Comparison of Nicox's Net Margin %

For the Biotechnology subindustry, Nicox's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nicox's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nicox's Net Margin % distribution charts can be found below:

* The bar in red indicates where Nicox's Net Margin % falls into.


;
;

Nicox Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Nicox's Net Margin for the fiscal year that ended in Dec. 2023 is calculated as

Net Margin=Net Income (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-20.881/6.646
=-314.19 %

Nicox's Net Margin for the quarter that ended in Jun. 2024 is calculated as

Net Margin=Net Income (Q: Jun. 2024 )/Revenue (Q: Jun. 2024 )
=-4.277/6.069
=-70.47 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Nicox  (XPAR:ALCOX) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.


Nicox Net Margin % Related Terms

Thank you for viewing the detailed overview of Nicox's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Nicox Business Description

Traded in Other Exchanges
Address
Rue Evariste Galois, Emerald Square, Batiment C, Sundesk Sophia Antipolis, Biot, FRA, 06410
Nicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Its lead program in clinical development is NCX 470 (bimatoprost grenod), a novel nitric oxide-donating bimatoprost eye drop, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company also has a preclinical research program on NCX 1728, a nitric oxide-donating phosphodiesterase-5 inhibitor, with Glaukos. Its first product, VYZULTA in glaucoma, licensed exclusively worldwide to Bausch + Lomb, is available commercially in the U.S. and over 15 other territories. Nicox generates revenue from ZERVIATE in allergic conjunctivitis, licensed in multiple geographies.

Nicox Headlines

No Headlines